Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellistem®sEV-OA in Knee Osteoarthritis
NCT06431152Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cellistem sEV-OA in osteoarthritis (OA) (3 arms). Primary endpoint: Adverse Event at 12 months. Started Jun 2024; status: recruiting.
02
Drugs
Cellistem sEV-OA
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06431152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431152.